Half-year report · Q2

Period2025-01-01 → 2025-06-30
Filed2025-08-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥251m2025-01-01 → 2025-06-30Cons.Net sales
Revenue¥636m2024-01-01 → 2024-12-31Cons.Net sales (5-year summary)
Revenue¥316m2024-01-01 → 2024-06-30Cons.Net sales
Operating income−¥1.1bn2025-01-01 → 2025-06-30Cons.Operating income
Operating income−¥1.1bn2024-01-01 → 2024-06-30Cons.Operating income
Ordinary income−¥1.1bn2025-01-01 → 2025-06-30Cons.Ordinary income
Ordinary income−¥2.1bn2024-01-01 → 2024-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.1bn2024-01-01 → 2024-06-30Cons.Ordinary income
Profit before tax−¥1.1bn2025-01-01 → 2025-06-30Cons.Income before income taxes
Profit before tax−¥1.1bn2024-01-01 → 2024-06-30Cons.Income before income taxes
Net income (owners)−¥1.1bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥2.2bn2024-01-01 → 2024-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.1bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent
Net income−¥1.1bn2025-01-01 → 2025-06-30Cons.Profit loss
Net income−¥1.1bn2024-01-01 → 2024-06-30Cons.Profit loss
Total assets¥1.6bnat 2025-06-30Cons.Assets
Total assets¥2.8bnat 2024-12-31Cons.Assets
Total assets¥3.7bnat 2024-06-30Cons.Total assets (5-year summary)
Total liabilities¥244mat 2025-06-30Cons.Liabilities
Total liabilities¥297mat 2024-12-31Cons.Liabilities
Net assets / equity¥1.4bnat 2025-06-30Cons.Net assets
Net assets / equity¥2.5bnat 2024-12-31Cons.Net assets
Net assets / equity¥3.2bnat 2024-06-30Cons.Net assets (5-year summary)
Cash and deposits¥1.1bnat 2025-06-30Cons.Cash and deposits
Cash and deposits¥2.1bnat 2024-12-31Cons.Cash and deposits
Cash & equivalents¥1.1bnat 2025-06-30Cons.Cash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31Cons.Cash and cash equivalents
Cash & equivalents¥3.0bnat 2024-06-30Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2023-12-31vCons.Cash and cash equivalents
Operating cash flow−¥995m2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.4bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥222m2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥16m2025-01-01 → 2025-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥13m2024-01-01 → 2024-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7m2024-01-01 → 2024-06-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥14m2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities
Financing cash flow¥567m2024-01-01 → 2024-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥279m2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-55.292025-01-01 → 2025-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-121.642024-01-01 → 2024-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-63.252024-01-01 → 2024-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio85.1%at 2025-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio89.3%at 2024-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio87.2%at 2024-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 8
SegmentItemPeriodValue
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥1.0bn
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥251m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥251m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥51m
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥1.1bn
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥316m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥316m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥24m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 418
ItemContextValueUnit
Other caPrior1YearInstant156174000JPY
Other caCurrentQuarterInstant98621000JPY
Current assetsPrior1YearInstant2737717000JPY
Current assetsCurrentQuarterInstant1589155000JPY
Investments and other assetsPrior1YearInstant34397000JPY
Investments and other assetsCurrentQuarterInstant46429000JPY
Noncurrent assetsPrior1YearInstant34397000JPY
Noncurrent assetsCurrentQuarterInstant46429000JPY
AssetsPrior1YearInstant2772115000JPY
AssetsCurrentQuarterInstant1635585000JPY
Accounts payable tradePrior1YearInstant2000000JPY
Accounts payable tradeCurrentQuarterInstant306000JPY
Current portion of long term loans payablePrior1YearInstant19992000JPY
Current portion of long term loans payableCurrentQuarterInstant18406000JPY
Accounts payable otherPrior1YearInstant151733000JPY
Accounts payable otherCurrentQuarterInstant129949000JPY
Income taxes payablePrior1YearInstant28526000JPY
Income taxes payableCurrentQuarterInstant6956000JPY
Other clPrior1YearInstant20713000JPY
Other clCurrentQuarterInstant28607000JPY
Current liabilitiesPrior1YearInstant222965000JPY
Current liabilitiesCurrentQuarterInstant184225000JPY
Long term loans payablePrior1YearInstant8410000JPY
Long term loans payableCurrentQuarterInstant-JPY
Asset retirement obligations nclPrior1YearInstant39286000JPY
Asset retirement obligations nclCurrentQuarterInstant39607000JPY
Other nclPrior1YearInstant26097000JPY
Other nclCurrentQuarterInstant20630000JPY
Noncurrent liabilitiesPrior1YearInstant73794000JPY
Noncurrent liabilitiesCurrentQuarterInstant60237000JPY
LiabilitiesPrior1YearInstant296760000JPY
LiabilitiesCurrentQuarterInstant244463000JPY
Capital stockPrior1YearInstant2447707000JPY
Capital stockCurrentQuarterInstant10996000JPY
Capital surplusPrior1YearInstant6198916000JPY
Capital surplusCurrentQuarterInstant2192775000JPY
Retained earningsPrior1YearInstant-6253962000JPY
Retained earningsCurrentQuarterInstant-865172000JPY
Treasury stockPrior1YearInstant-222000JPY
Treasury stockCurrentQuarterInstant-222000JPY
Shareholders equityPrior1YearInstant2392439000JPY
Shareholders equityCurrentQuarterInstant1338376000JPY
Valuation difference on available for sale securitiesPrior1YearInstant-3430000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant-6168000JPY
Foreign currency translation adjustmentPrior1YearInstant86346000JPY
Foreign currency translation adjustmentCurrentQuarterInstant58914000JPY
Valuation and translation adjustmentsPrior1YearInstant82915000JPY
Valuation and translation adjustmentsCurrentQuarterInstant52746000JPY
Net assetsPrior1YearInstant2475354000JPY
Net assetsCurrentQuarterInstant1391122000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-12-31pass rounding
balance sheet identityconsolidated 2025-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-12-31pass
statement vs summary · net assetsconsolidated 2025-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · total assetsconsolidated 2024-12-31pass
statement vs summary · total assetsconsolidated 2025-06-30pass